4//SEC Filing
GALAKATOS NICHOLAS 4
Accession 0001209191-18-053536
CIK 0001724344other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 9:38 PM ET
Size
18.5 KB
Accession
0001209191-18-053536
Insider Transaction Report
Form 4
GALAKATOS NICHOLAS
Director10% Owner
Transactions
- Conversion
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28−6,702,213→ 0 total(indirect: See Footnote)→ Common Stock (323,341 underlying) - Conversion
Common Stock
2018-09-28+412,583→ 1,170,010 total(indirect: See Footnote) - Conversion
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28−8,552,024→ 0 total(indirect: See Footnote)→ Common Stock (412,583 underlying) - Conversion
Common Stock
2018-09-28+361,829→ 361,829 total(indirect: See Footnote) - Conversion
Common Stock
2018-09-28+323,341→ 685,170 total(indirect: See Footnote) - Purchase
Common Stock
2018-09-28$15.00/sh+453,395$6,800,925→ 1,623,405 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock
2018-09-28−7,500,000→ 0 total(indirect: See Footnote)→ Common Stock (361,829 underlying)
Footnotes (3)
- [F1]Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
- [F3]This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.
Documents
Issuer
Entasis Therapeutics Holdings Inc.
CIK 0001724344
Entity typeother
Related Parties
1- filerCIK 0001252522
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 9:38 PM ET
- Size
- 18.5 KB